Agios Pharmaceuticals, Inc. AGIO
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. 10-K, Item 1
- Headquarters
- Cambridge, MA
- CEO
- Brian Goff
- Next results
- around Feb 11, 2027
AGIO among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
32 new risk paragraphs. 10-K filed Feb 12, 2026 against Feb 13, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 10 checks found nothing to note
-
Cash from operations −$373.0M vs net income −$412.8M (FY ending Dec 31, 2025)
-
Inventory +19.2% ($27.6M to $32.9M) vs revenue +48.0% ($36.5M to $54.0M), -28.8 pts apart
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Table of Content s; Revenue Recognition - PYRUKYND® Product Revenue
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
32 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
The development and commercialization of PYRUKYND® or AQVESME™ could be unsuccessful if:
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Ongoing or unanticipated geopolitical events in countries where we may to have clinical trial sites could also negatively impact our ability to initiate, enroll and retain patients in, and conduct clinical trials.
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with foreign exchange fluctuations, compliance with foreign manufacturing, customs, shipment and storage requirements, cultural differences in medical practice and clinical research, diminished protection of intellectual…
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
For example, the USPI for PYRUKYND® includes a warning regarding the risk of potential hepatoceullar injury, and the USPI for AQVESME™ contains a boxed warning regarding the potential for hepatocellular injury. In addition, to mitigate the risk of hepatocellular injury, AQVESME™ is available only through the REMS program approved by the…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $14.2M | $26.8M | $36.5M | $54.0M |
| Net income | −$231.8M | −$352.1M | $673.7M | −$412.8M |
| Operating cash flow | −$309.5M | −$296.1M | −$389.8M | −$373.0M |
| Free cash flow | −$314.4M | −$297.1M | −$391.5M | −$377.3M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$54.0M ▲ 48.0% in FY2025−$412.8M in FY2025−$377.3M in FY2025
Recent filings
6 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026James Burns (Chief Legal Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 19,754 shares, runs to Dec 10, 2027
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
Planned saleOct 26, 2026SARAH GHEUENS (Officer) gave notice of a planned sale of 7,866 shares worth about $296K Form 144, approximate sale date Oct 26, 2026, under a 10b5-1 plan adopted May 1, 2026
-
Planned saleOct 22, 2026SARAH GHEUENS (Officer) gave notice of a planned sale of 500 shares worth about $19K Form 144, approximate sale date Oct 22, 2026, under a 10b5-1 plan adopted May 1, 2026
About the company
Agios Pharmaceuticals, Inc., Cambridge, MA · from the 10-K filed Feb 12, 2026
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.
- Headquarters
- Cambridge, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AGIO/export.csv") into a cell.